News and Trends 12 Sep 2017
British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic
Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […]